Related Experiment Videos

The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective

L Kurland1

  • 1Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden. lisa.kurland@medsci.uu.se

Minerva Medica
|November 8, 2003
PubMed

Insights

High blood pressure (hypertension) is a major risk factor for heart disease and stroke. Pharmacogenetics, the study of genetic influences on drug response, offers potential for personalized hypertension treatment.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenetics
  • Genetics

Background:

  • Coronary heart disease is a leading cause of death globally.
  • Hypertension affects 25% of adults and is a primary risk factor for heart attack and stroke.
  • Current methods cannot predict individual responses to antihypertensive drugs, despite their proven efficacy.

Purpose of the Study:

  • To provide a general background on pharmacogenetics and its applications.
  • To review recent pharmacogenetics studies on antihypertensive drug efficacy.
  • To explore the potential of pharmacogenetics in personalized hypertension management.

Main Methods:

  • Review of existing literature on pharmacogenetics and hypertension.
  • Analysis of pharmacogenetic studies concerning antihypertensive drug response.
  • Focus on the angiotensin II type 1 receptor antagonist, irbesartan.

Main Results:

  • Genetic factors significantly influence blood pressure variation (30-60%).
  • Drug response variability in hypertension treatment is partly heritable.
  • Recent studies investigate the pharmacogenetics of irbesartan's antihypertensive effects.

Conclusions:

  • Pharmacogenetics holds promise for optimizing hypertension treatment by predicting individual drug responses.
  • Personalized medicine approaches in cardiovascular disease management are increasingly important.
  • Further research in pharmacogenetics can lead to improved patient outcomes in hypertension care.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...